Kuros - Didier Cowling
Swiss biotech firm Cytos Biotechnology is not only changing CEO but changing its name.
The firm, which focuses on developing targeted immunotherapies through its VLP B-cell vaccines platform, will now be known as Kuros Biosciences after its acquisition of Kuros Biosurgery, and current CEO Christian Itin is stepping down as CEO but remaining Chairman of the Board.
Replacing him is Kuros Biosurgery CEO Didier Cowling who was elected to the position by the newly constituted Board.
“Cytos has received overwhelming support by our shareholders for the acquisition of Kuros Biosurgery Ltd,” the departing CEO said.
“With the closing of the transaction most existing members of the Board will step down and new members of the Board of Directors have been elected. I would like to thank the outgoing Board members for their continued support and welcome the new members of the board and executive management.”